No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID
Abstract
Long COVID (LC), or post ‐ COVID ‐ 19 condition (PCC), is a heterogenous disorder characterized by persistence of symptoms >12 weeks after COVID ‐ 19 infection that cannot be explained by alternative causes. 1 Common symptoms include breathlessness, fatigue and cognitive difficulties. 1,2 Although hospitalization with acute COVID ‐ 19 increases the risk of LC, the majority of people with LC were never hospitalized. 2 An international research effort to understand the biological mechanisms driving symptom persistence, including breathlessness, has not identified a single or unifying explanation although most pathways converge on a dysregulated inflammatory response. 3 A prominent hypothesis is that individuals with LC are prothrombotic and develop “ microclots ” that lodge in the peripheral vasculature causing local tissue hypoxia and symptoms including breathlessness and post ‐ exertional malaise. 3 This hypothesis stems from observations in acute COVID ‐ 19 of a hypercoagulable state with impaired fibrinolysis and increased thrombotic risk, together with reports of amyloid ‐ fibrin(ogen) microaggregates in LC. 4 – 6 This prothrombotic hypothesis has been used to